Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs.
Leading drug OС000459Therapeutic focus: asthma and other respiratory diseases
Currently preclinical and 1/2 clinical trials have been successfully conducted and shown a high efficacy and safety.
Eleventa is a Russian biotechnology company founded in 2012 to develop and commercialize innovative products for the treatment of asthma and other allergic and inflammatory respiratory diseases.
OС000459, selective antagonist of CRTH2 receptors
Therapeutic focus: asthma and other respiratory diseases: allergic rhinitis, conjunctivitis, atopic dermatitis, and eosinophilic esophagitis.
Status: Phase 3 clinical trials.
Maxwell Biotech Group
+7 (495) 726-52-53
12/19, build.1, Verkhnyaya Radishchevskaya str.
Moscow, 109240, Russia
© Eleventa, 2012—2020